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Abstract
Markers of biological aging have potential utility in primary care and public health. We 
developed a model of age based on untargeted metabolic profiling across multiple plat-
forms, including nuclear magnetic resonance spectroscopy and liquid chromatography–
mass spectrometry in urine and serum, within a large sample (N = 2,239) from the UK 
Airwave cohort. We validated a subset of model predictors in a Finnish cohort including 
repeat measurements from 2,144 individuals. We investigated the determinants of ac-
celerated aging, including lifestyle and psychological risk factors for premature mor-
tality. The metabolomic age model was well correlated with chronological age (mean 
r = .86 across independent test sets). Increased metabolomic age acceleration (mAA) 
was associated after false discovery rate (FDR) correction with overweight/obesity, dia-
betes, heavy alcohol use and depression. DNA methylation age acceleration measures 
were uncorrelated with mAA. Increased DNA methylation phenotypic age acceleration 
(N = 1,110) was associated after FDR correction with heavy alcohol use, hypertension 
and low income. In conclusion, metabolomics is a promising approach for the assess-
ment of biological age and appears complementary to established epigenetic clocks.
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1  | INTRODUC TION
Aging has been defined as the “time-dependent decline of functional 
capacity and stress resistance, associated with increased risk of 
morbidity and mortality” (Burkle et al., 2015). Environmental stress-
ors, including lifestyle and social adversity (Stringhini et al., 2018), 
psychological disorders (Chiu et al., 2018; Wolf & Morrison, 2017), 
and genetic factors (McDaid et al., 2017) may influence the aging 
process, leading to differing aging rates. Traditionally, quantitative 
assessment of “the rate of aging” relies on the analysis of mortality 
curves of populations. However, at the level of a single individual, 
this method does not allow assessment of the state of aging (i.e., 
the state of the functional decline) and a prediction of the risk of 
morbidity and remaining life expectancy. In contrast, markers of “bi-
ological age” that can be assessed at any point in the lifespan may 
allow, for instance, early identification of individuals or groups at risk 
of developing age-related disease or frailty and enable targeted in-
terventions (Ferrucci, Levine, Kuo, & Simonsick, 2018).
Since aging is a process that affects almost all tissues and or-
gans and involves crosstalk between multiple physiological systems, 
there has been increased research into composite markers of aging, 
involving multiple parameters (Jylhävä, Pedersen, & Hägg, 2017). 
Biological age scores have been developed by combining established 
clinical biomarkers (Levine, 2013) (Belsky et al., 2015) and have been 
associated with measures of functional decline such as cognitive 
ability (Belsky et al., 2015). Modern “omics” platforms have provided 
new opportunities for the systematic and agnostic assessment of bi-
ological aging. Analysis of genome-wide DNA methylation (Hannum 
et al., 2013; Horvath, 2013; Levine et al., 2018), mRNA (Peters et al., 
2015) and miRNAs (Huan et al., 2018) has allowed the development 
of multi-parameter “omic clocks,” built upon molecular changes that 
tick at an average rate consistent with chronological age. DNA meth-
ylation age acceleration, defined as having a greater DNA methyla-
tion age than chronological age (i.e., a faster than average “ticking 
rate”), is associated with multiple noncommunicable disease (NCD) 
risk factors (Fiorito et al., 2019) and predictive of aging outcomes 
such as frailty, cognitive decline (Horvath et al., 2016) and all-cause 
mortality (Chen et al., 2016; Dugue et al., 2018).
Metabolomics, the profiling of small molecules, is a promising 
technology for the comprehensive assessment of biological aging. 
As the final product of cellular metabolism, metabolites may pro-
vide a more complete picture of biological processes and a stronger 
phenotypic representation than other “omic profiles.” Although me-
tabolomic studies have reported strong associations between me-
tabolites and age, these have been of limited sample size (Chaleckis, 
Murakami, Takada, Kondoh, & Yanagida, 2016; Rist et al., 2017) or 
employed targeted analyses with only partial coverage of the full 
metabolome (Auro et al., 2014) (Hertel et al., 2016; Yu et al., 2012). 
Larger sample sizes can provide more precise, and potentially less 
biased, assessments of a typical biological age in a given population, 
while the use of multiple analytical platforms can provide a more 
complete assessment of metabolic processes relevant to biological 
aging. Only one study provided an overall assessment of biological 
aging, based on urinary proton nuclear magnetic resonance spec-
troscopy (NMR), reporting that metabolomic age was associated 
with time to death, after adjustment for chronological age and other 
risk factors (Hertel et al., 2016).
In the present study, we aimed to develop a systematic assess-
ment of biological age using untargeted metabolomics. We have 
employed multiple metabolomic analytical platforms, providing un-
precedented metabolome coverage, to develop a predictive model 
of age, within a large sample from the Airwave cohort of employees 
of the police service in Great Britain. A second cohort was used for 
longitudinal validation of selected metabolic age predictors. To as-
sess whether deviations between the predicted metabolomic age 
and chronological age reflect differences in biological aging rate, 
we have investigated associations with risk factors of premature 
mortality, including the WHO “25 × 25” risk factors (World Health 
Organisation, 2013) (hypertension, diabetes, obesity, smoking, 
alcohol use and physical inactivity) and socio-economic and psy-
chological risk factors (income, depression, anxiety, post-traumatic 
stress disorder (PTSD)). Finally, to assess whether metabolomic age 
is complementary to established epigenetic assessments of age, we 
have assessed the relationship between metabolomic and epigenetic 
aging, and their relative associations with risk factors.
2  | RESULTS
2.1 | Study population
The study population comprised 2,238 participants of the Airwave 
cohort with full metabolomic data. A 60.5% of participants were 
male, and mean age was 41.24 years (SD: 9.1, range: 19.2–65.2 years). 
Most participants (97.5%) were of white British ethnicity, and 27.8% 
of participants were educated to degree level. The demographic 
characteristics of this sample are representative of the wider cohort 
(Elliott et al., 2014).
2.2 | Metabolomic age modelling
Metabolomic data were acquired from both urine and serum sam-
ples using multiple proton nuclear magnetic resonance spectros-
copy (NMR) and ultra-performance liquid chromatography–mass 
spectrometry (UPLC-MS) platforms, providing in total nine different 
metabolomic data types (Table 1).
2.2.1 | Age prediction by platform
We first assessed the age prediction of each metabolomic plat-
form separately (Table 1). We followed a bootstrapping procedure 
and trained elastic net models of age in re-sampled training por-
tions (80%) of our data 100 times, for each metabolomic platform. 
Predictive performance was then assessed in the independent 
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training sets (remaining 20% of data) to provide unbiased estimates. 
The best performing platforms were reversed-phase UPLC-MS in 
positive mode in urine (“uRPOS”) and lipid-targeted reversed-phase 
UPLC-MS in positive mode in serum (“sLPOS”) that had mean cor-
relations between predicted and chronological age of 0.83 (boot-
strap 95% confidence interval (CI): 0.80, 0.85) and 0.80 (95% CI 0.77, 
0.82), respectively, across testing sets. The worst performing plat-
forms were NMR in urine (NOESY experiment, “uNMR”) and Bruker 
IVDr Lipoprotein Subclass Analysis derived from NMR in serum 
(“sBiLISA”) with mean correlations between predicted and chrono-
logical age of 0.58 (CI: 0.52, 0.62) and 0.45 (95% CI 0.39,0.51), re-
spectively, across testing sets.




MS HPOS in 
serum
sHPOS Hydrophilic interaction chromatography (HILIC), 
provides enhanced separation of small, highly 
polar molecules ionized in positive mode
1,505 .62 (.56, .67) 5.69 (5.34, 6.07)
MS LNEG in 
serum
sLNEG Lipid-targeted reversed-phase chromatography 
provides maximal resolution of fatty acids, 
triglycerides, and phospholipids, ionized in 
negative mode
5,833 .71 (.67, .75) 5.07 (4.76, 5.37)
MS LPOS in 
serum
sLPOS  Lipid-targeted reversed-phase chromatography, 
ionized in positive mode
7,211 .80 (.77, .83) 4.29 (4.06, 4.55)
NMR BiLISA in 
serum
sBiLISA Quantifies cholesterol, free cholesterol, 
phospholipids, triglycerides, apolipoprotein 
A1, A2, B and particle numbers for the primary 
lipoproteins and their subclasses
105 .45 (.39, .51) 6.49 (6.19, 6.79)
NMR CPMG in 
serum
sNMR Highly robust, repeatable and precise platform 23,571 .65 (.62, .69) 5.53 (5.21, 5.82)
MS HPOS in urine uHPOS Hydrophilic interaction chromatography (HILIC), 
provides enhanced separation of small, highly 
polar molecules ionized in positive mode
7,325 .77 (.74, .80) 4.62 (4.27, 4.95)
MS RNEG in urine uRNEG Reversed-phase chromatography targets small 
moderately polar molecules, ionized in negative 
mode
14,481 .79 (.75, .82) 4.42 (4.14, 4.70)
MS RPOS in urine uRPOS  Reversed-phase chromatography, ionized 
in positive mode
14,300 .83 (.80, .85) 4.17 (3.92, 4.38)
NMR NOESY in 
urine
uNMR Highly robust, repeatable and precise platform 24,493 .58 (.52, .62) 5.88 (5.62, 6.20)
aRefers to spectral data points in uNMR and sNMR, to lipoprotein and subclass measures in sBiLISA and retention time-m/z pairs in MS analysis. 
br and MAE refer to the mean Pearson's correlation and mean absolute error, respectively, with chronological age across the independent test sets, 
with brackets showing bootstrapped 95% confidence internals. 
F I G U R E  1   Summary of metabolomic age prediction. (a) Distribution of Pearson's correlation coefficient (r) between chronological and 
predicted age across bootstrapped test sets. (b) Metabolomic age plotted against chronological age. (c) Distribution of metabolomic age 
acceleration scores
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2.2.2 | Multi-platform metabolomic age
To find the combination of metabolomic data sets that provided the 
best age prediction performance, we combined the metabolomic 
data sets and constructed further elastic net models of age, sequen-
tially leaving one platform out each time. Predictive performance 
of age (minimization of mean squared error (MSE) in 10-fold cross-
validation was improved by use of only the four following platforms 
(Figure S1): sBiLISA, sLPOS, uRPOS and hydrophilic interaction 
UPLC-MS in positive mode in urine (“uHPOS”).
These four platforms were retained to give a total of 28,941 meta-
bolic features (retention time-mz pairs or lipoprotein measurements) 
for the final stage of model building. To define a stable metabolomic 
age score for each participant, we again followed the bootstrapping 
procedure of re-sampling training and testing portions of this data 
set 100 times. Prediction of age in the independent training sets was 
highly accurate and stable across all re-samplings with mean cor-
relation between predicted and chronological age of 0.86 (95% CI: 
0.85, 0.88) (Figure 1a). Mean absolute error (MAE) across training 
sets was on average 3.71 years, with a bootstrap 95% CI of 3.37 to 
3.96 years. The metabolomic age of each participant was assigned 
as their mean predicted age across the 100 bootstrapped models 
(Figure 1b). Metabolomic age acceleration (mAA) was then defined 
as the difference, at a given age, between chronological and metab-
olomic age (Figure 1c).
Age prediction was also stable across different population areas 
(Table S1, Figure 2). Correlation between predicted and chronological 
age across different police services of Great Britain (using remaining 
study areas as training sets to predict age in each respective study area) 
ranged from 0.82 in Scotland to 0.87 in the North West of England.
2.3 | Metabolomic age predictors
The median number of metabolic features selected into each model 
in the final stage was 1,311 (range: 498–9,754) (see Data Set S1 for 
list of predictors along with Data Set S2 annotation information). 62 
metabolic features were present in 100% of models, 450 metabolic 
features were present in at least 75%, 1,080 metabolic features were 
present in at least 50%, and 2,990 were present in only one model. 
Features present in at least 75% included 8 lipoprotein subclasses 
from sBiLISA and 207, 81 and 154 features (retention time-m/z pairs) 
from the sLPOS, uHPOS and uRPOS platforms, respectively.
Pathway enrichment analysis, using the Mummichog algorithm 
performed across the UPLC-MS-derived features that were present 
in at least 75% of models identified enrichment in thirteen meta-
bolic pathways (Table 2, Figure 3): vitamin E metabolism; lysine 
metabolism; urea cycle/amino group metabolism; vitamin D3 (chole-
calciferol) metabolism; tryptophan metabolism; carnitine shuttle; 
phosphatidylinositol phosphate metabolism; aspartate and aspar-
agine metabolism; drug metabolism—cytochrome P450; biopterin 
metabolism; xenobiotic metabolism; butanoate metabolism; and 
tyrosine metabolism.
We examined concentration changes of eleven metabolites in-
cluded in over 50% of age prediction models, that were available 
in an independent cohort, the Northern Finnish Birth Cohort 1966, 
F I G U R E  2   Metabolomic age plotted against chronological age across different independent study areas. Seven models in this analysis 
were trained separately on data from participants in six out of the seven study areas and validated with data in the remaining study area 
shown
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that had serum NMR metabolomic data measured at two ages, 31 
and 46 years, among 2,144 individuals. Nine of these metabolites 
(82%) changed significantly with age (validation p < .005), in the same 
direction as predicted in the metabolomic age model (Table S2).
2.4 | Comparison with DNA methylation age
DNA methylation age was assessed for 1,110 participants, using 
the multi-tissue clock derived by Horvath (Horvath, 2013) and the 
blood-derived clock of Hannum et al. (2013) both trained on chrono-
logical age, and the clock of Levine et al. (2018) that was trained 
on “phenotypic age.” Demographic characteristics for this sample 
were similar to those for participants with metabolomic age avail-
able (age range = 19.9–65.2 years, 60% male). DNA methylation age 
measures were strongly correlated with chronological age (Table 3) 
and metabolomic age (for 837 participants with both metabolomic 
and epigenetic data, Table 3). Mean age acceleration scores were 
0.00 (standard deviation (SD): 3.65), 0.00 (SD: 3.19) and 0.01 (SD: 
5.12) years for Horvath, Hannum and Phenotypic ages, respectively, 
while mean mAA was 0.00 years (SD: 2.13 years). No correlation was 
observed between epigenetic age acceleration measures and mAA 
(Table 3).
2.5 | Risk factors of age acceleration
Figure 4 and Table S3 shows adjusted associations with age accel-
eration measures for noncommunicable disease and psychological 
risk factors (adjusted for sex, ethnicity, study centre, income, hyper-
tension, diabetes, body mass index (BMI), smoking, alcohol intake, 
physical activity, and fruit, vegetable, meat and fish consumption). 
We observed increases (p < .05) in mAA with overweight, obesity, 
heavy drinking, diabetes, depressive symptoms, depression, anxiety 
and post-traumatic stress disorder ranging from 0.32 (interpretable 
as years of age acceleration, 95% confidence interval (CI): 0.00, 0.65) 
for anxiety compared to those without any symptoms of anxiety, to 
0.87 (95% CI: 0.60, 1.13) for obesity (BMI ≥ 30 kg/m2) compared to 
those of normal weight (BMI < 25 kg/m2). Associations of mAA with 
overweight, obesity, heavy drinking, diabetes, depressive symptoms 
and depression remained significant after correction for false dis-
covery rate.
Increases with DNA methylation age acceleration were ob-
served for low income (Hannum: 0.43, 95% CI: −0.06, 0.92), anxiety 
(Hannum, 0.68, 95% CI: −0.01, 1.38) and PTSD (Horvath: 0.95, 95% 
CI: −0.24, 2.13) that were of a larger size than for mAA. Effect sizes 
with phenotypic age acceleration were generally larger than for the 
other age acceleration measures and in the expected direction for all 
risk factors, except for diabetes. In particular, associations between 
phenotypic age acceleration with heavy alcohol use (2.51, 95% CI: 
0.88, 4.13), hypertension (1.09, 95% CI: 0.06, 2.13) and low income 
(1.59, 95% CI: 0.81, 2.36) remained significant after correction for 
false discovery rate.
2.6 | Sensitivity analysis
To avoid the possibility of metabolic features being selected into 
models due to their association with body mass index (BMI) (that 
increases with chronological age and is associated with wide-
spread disturbances in the metabolome (Elliott et al., 2015)), we 
repeated the metabolomic age modelling process, with BMI of 
participants included as a predictor, forced into all models. Similar 
results were obtained (mean correlation across test set = 0.86, 
bootstrap 95% CI: 0.84, 0.88). Enriched metabolic pathways 
among these models were similar (Table S4). mAA was calculated 
from these models as before but additionally adjusting for BMI 
to remove its contribution from the mAA scores. Similar associa-
tions with the new BMI-adjusted mAA score and risk factors were 
observed (Table S5).
3  | DISCUSSION
We have demonstrated in a large nationwide cohort study that me-
tabolomic profiling may be used to predict chronological age with high 
accuracy among working-age adults. We employed a wide range of me-
tabolomic platforms to provide the broadest metabolome coverage yet 
TA B L E  2   Significantly enriched metabolic pathways among 






Vitamin E metabolism 16 37 .0129
Lysine metabolism 11 29 .0161
Urea cycle/amino group 
metabolism
17 52 .0170
Vitamin D3 (cholecalciferol) 
metabolism
5 10 .0185
Tryptophan metabolism 20 69 .0218










Biopterin metabolism 5 15 .0354
Xenobiotic metabolism 18 71 .0397
Butanoate metabolism 7 26 .0474
Tyrosine metabolism 22 91 .0478
aThe number of model predictors (sLPOS, uHPOS and uRPOS) matched 
to each pathway. 
bThe number of metabolites in the whole sLPOS, uHPOS and uRPOS 
data sets matched to each pathway. 
cp values adjusted for type 1 error through Gamma-based permutation 
procedure.. 
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presented in population-based studies. We found that metabolomic 
age acceleration, defined as having a greater predicted metabolomic 
age than chronological age, was associated with overweight/obesity, 
high alcohol intake, diabetes and depression. We did not observe an 
association between epigenetic age acceleration and metabolomic age 
acceleration, suggesting these measures capture separate aspects of 
the aging process. We observed larger effect sizes of epigenetic than 
metabolomic age acceleration with anxiety-related disorders.
The correlation between chronological and our measure of me-
tabolomic age (mean r = .86 in the validation data sets) was some-
what lower than that of the Hannum epigenetic age clock in our 
cohort (r = .92) but greater than reported for other biological aging 
markers, including the measure based on urinary NMR data (Hertel 
et al., 2016) (r = .53 in men and 0.61 in women in validation data 
set), the blood transcriptomic clock (Peters et al., 2015) (r = .35–
.74 depending on cohort) and telomere length (r ~ .3 (Muezzinler, 
Zaineddin, & Brenner, 2013)). Biological aging markers aim to better 
capture the body's rate of decline or physiological breakdown than 
chronological age itself and should therefore also be more predictive 
of mortality and age-related disease. The associations, we observed 
between accelerated metabolomic aging and factors known to in-
crease risk of mortality, suggest that metabolomic age may capture 
this physiological decline.
Strong direct associations with mAA were observed with diabe-
tes, overweight and obesity. These conditions are forms of metabolic 
dysregulation, and their additional metabolic burden may increase 
the rate of decline of the metabolic systems of the body. Genetic 
predisposition to longevity is associated with low levels of abdominal 
visceral fat (Sala et al., 2015) and many different conditions that pro-
long lifespan in animal models also improve obesity-related condi-
tions. Furthermore, obesity has been linked to telomere shortening, 
and drastic measures to combat morbid obesity like bariatric surgery 
can cause a recovery in telomere length (Laimer et al., 2015). Much 
is now known about the aging process at the molecular level primar-
ily from experimental work. López-Otín, Blasco, Partridge, Serrano, 
and Kroemer, (2013) proposed nine “hallmarks of aging” that may be 
expected to have detectable effects on the metabolome and over-
lap significantly with the effects of metabolic disorders (López-Otín, 
Galluzzi, Freije, Madeo, & Kroemer, 2016). For instance, the hallmark 
“deregulated nutrient signalling” refers to pathways that sense and 
respond to nutrient availability such as “insulin and IGF1 signalling” 
(IIS) pathway, which is altered in diabetes.
We observed higher mAA for individuals with depressive symp-
toms and those with frank depression. Both psychological distress 
and major depression were reported to have similar hazard ratios for 
mortality in a recent prospective study (Chiu et al., 2018). Consistent 
evidence demonstrates a bi-directional association between depres-
sion and so-called metabolic syndrome, suggesting common patho-
logical roots (Marazziti, Rutigliano, Baroni, Landi, & Dell'Osso, 2014). 
Proposed pathophysiological commonalities include abnormal acti-
vation of the hypothalamic–pituitary–adrenal (HPA) axis and altered 
levels of circulating leptin and ghrelin, two peripheral hormones that 
are classically implicated in the homeostatic control of food intake. 
While in this cross-sectional study we cannot disentangle the causal 
F I G U R E  3   Metabolic network visualisation of significantly enriched pathways based on the manually curated KEGG global metabolic 
network (Chong et al., 2018). The metabolites of significantly enriched pathways are represented as nodes on the network. Empty nodes 
represent compounds identified from the feature list by Mummichog but not significant, while solid nodes represent significantly enriched 
features. Note not all metabolites from the KEGG global network are displayed
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direction between depression and mAA, a study of biological aging 
among elderly people found that accelerated biological age was as-
sociated with depressive symptoms at baseline and was also predic-
tive of depressive symptoms at follow-up (Brown et al., 2017).
In pathway analysis of metabolomic age model predictors, we 
observed enrichment of the tryptophan, tyrosine and biopterin met-
abolic pathways that relate to the aging hallmark “altered intercel-
lular communication.” Tyrosine is required for signal transduction 
through incorporation into protein kinases, while tryptophan and 
biopterin are necessary for synthesis of neurotransmitters including 
dopamine, norepinephrine, epinephrine, serotonin and melatonin. 
Alterations to neurotransmitter levels may underlie the associations 
we observed between mAA with depressive symptoms and depres-
sion. Enrichment of pathways including lysine metabolism, carnitine 
shuttle, urea cycle, and aspartate and asparagine metabolism di-
rectly relate to mitochondrial dysfunction, which has long been rec-
ognized as an aging hallmark (López-Otín et al., 2013). Dysfunctional 
mitochondria are major sources of genotoxic reactive oxygen spe-
cies (López-Otín et al., 2013), which impacts other aging hallmarks 
including genomic instability, altered intercellular communication 
and stem cell exhaustion (Ito et al., 2006). We observed enrichment 
of metabolism of vitamin E, a potent antioxidant and anti-inflamma-
tory agent that protects cell membranes from oxidative damage that 
can induce genome instability (Claycombe & Meydani, 2001), and of 
vitamin D3, whose production decreases with age (Gallagher, 2013).
We observed increases in Hannum and Horvath age acceler-
ation associated with anxiety, PTSD and low income that were 
generally of greater size than for mAA (although with wider con-
fidence intervals due to the smaller sample size). Meta-analyses 
have shown that both PTSD (Wolf & Morrison, 2017) and low 
socio-economic position (Fiorito et al., 2017) are associated with 
higher Hannum age acceleration. We did not observe any evidence 
for an association between depression and Hannum or Horvath 
age acceleration, suggesting epigenetic and metabolomic aging 
measures may be sensitive to separate dimensions of mental 
health. The DNA methylation clocks of Horvath and Hannum have 
been shown to perform well as markers of biological age since 
they are predictive of all-cause mortality, even after adjusting for 
chronological age and a variety of known risk factors, and are as-
sociated with physical measures of aging such as frailty and cogni-
tive decline (Horvath et al., 2016). However, other biological aging 
markers may add value in capturing different aspects of the aging 
process. Peters et al. (2015) reported that transcriptomic age was 
only moderately correlated with DNA methylation age and the 
different measures were associated with different aging pheno-
types. Similarly, Belsky et al. (2017) report only weak correlations 
between telomere length, DNA methylation age and a composite 
biomarker-based measure of biological aging among young adults. 
While metabolomic and DNA methylation age were correlated in 
our study, mAA and DNAmAA were not. This is likely because the 
platforms measure alterations related to different aging hallmarks: 
Horvath proposed that his clock measured maintenance of epigen-
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age relates to hallmarks including nutrient signalling, mitochon-
drial dysregulation and intra-cellular communication. Epigenetic 
age acceleration measures are predictive of cancer-related mor-
tality but not CVD (Dugue et al., 2018; Horvath et al., 2016) while 
the risk factors associated with mAA suggest it may be predictive 
of cardio-metabolic-related disease. Accelerated transcriptomic 
age was found to be similarly associated with CVD risk factors, 
although it was not related to mental health (Peters et al., 2015). 
Further research into biological aging may consider combining 
markers at different levels of biological organization to provide a 
more complete picture of the aging process.
We generally observed stronger associations between risk fac-
tors and phenotypic age acceleration than for the other aging mea-
sures. This is to be expected as DNA methylation phenotypic age 
was not trained on chronological age, as for the other measures, but 
trained on a composite measure of clinical markers, selected based 
on prediction of time to death. As a marker of biological age, rather 
than chronological age, this approach to training aging markers has 
obvious advantages in capturing the age-associated phenotypic 
changes most predictive of mortality and morbidity. However, this 
approach will also assess to a greater extent the early effects of 
disease, rather than the root molecular changes that underly the nor-
mal intrinsic aging process. It has been proposed that aging should 
be viewed as hierarchical in nature with changes at the molecular 
level (the “aging hallmarks”) underlying, and preceding, changes at 
the phenotypic level, which in turn underly levels of function and 
healthspan (Ferrucci et al., 2018). While training metabolomic age 
on mortality, as for phenotypic age, may increase sensitivity to risk 
factors, the current approach of assessment of molecular changes 
associated with chronological age therefore has other advantages 
in terms of identifying the root, intrinsic processes associated with 
biological aging, which may precede phenotypic changes.
This study has some limitations. The data analysed from Airwave 
were cross-sectional, based on a single biological sampling from par-
ticipants at a wide range of ages and we cannot therefore discount 
the contribution of cohort effects. However, pathways that were 
enriched in our models were related to endogenous physiological 
processes related to aging, and we validated selected metabolomic 
age predictors that were available in an independent cohort at two 
timepoints (15 years apart) in the early adult life of the same individ-
uals. We found that for most of these metabolites, changes over time 
were as predicted by the metabolomic age model. Our population 
F I G U R E  4   Associations between risk 
factors of premature mortality and age 
acceleration scores. Models adjusted 
for sex, ethnicity, study centre, income, 
hypertension, diabetes, BMI, smoking, 
alcohol intake, physical activity, and fruit, 
vegetable, meat and fish consumption. 
Bars show 95% confidence intervals. 
N (met) and N (epi) columns indicate 
number analysed for each category for 
metabolomic age and DNA methylation 
age measures, respectively
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only covered working-age adults and it is known that biological 
aging becomes more variable within the elderly. Further work is re-
quired to test the performance of our modelling approach for older 
populations.
The use of untargeted metabolomics presents both strengths and 
limitations. For untargeted analyses by UPLC-MS, there may be issues 
in matching features across different studies or data sets because of 
differences in retention time and mass accuracy in different runs of 
spectral acquisition. This is not the case for 1H NMR, however, since 
different features can be closely aligned across studies using appro-
priate preprocessing steps (Karaman et al., 2016). However, NMR is 
less sensitive than UPLC-MS and different molecules may produce 
overlapping signals in untargeted data sets introducing noise. Indeed, 
we found most NMR platforms were not selected for inclusion during 
our final modelling process. Structural annotation of relevant meta-
bolic features was outside the scope of the present study and may 
not even be possible for some predictors without current database 
matches. However, the aim of the study was to develop an overall as-
sessment of metabolic age rather than identify individual metabolic 
features. Indeed, the nature of the variable selection method used 
means that equally predictive models can be built on different sets 
of metabolites. We used the Mummichog pathway analysis tool to 
extract information at the pathway level, as the algorithm bypasses 
laboratory annotation based on the assumption that misidentifica-
tion will apply equally both to the feature set (metabolites included 
in the age prediction model) and the reference set (metabolites not 
selected into the model). The tool has been validated in separate data 
sets that have also undergone full laboratory annotation (Li et al., 
2013). We incorporated a range of MS platforms able to detect both 
lipophilic and hydrophilic molecules at low concentrations and NMR 
platforms able to detect larger structures such as lipoproteins that 
would be destroyed during MS acquisition. We also analysed both 
serum and urine that contain different sets of metabolites—more li-
pophilic molecules in serum and more polar molecules that are pres-
ent at higher concentrations in urine. Together, we assayed a large 
portion of the metabolome that would not be possible with current 
targeted methods. Other strengths include the incorporation of DNA 
methylation data, the wide age range of participants including those 
in early adult life where aging interventions may be most effective 
(Moffitt, Belsky, Danese, Poulton, & Caspi, 2017) and the use of vali-
dated psychological instruments.
In conclusion, we have developed a predictive indicator of aging 
based on broad metabolomic analysis among working-age adults. 
We found that while mAA, the difference between metabolomic and 
chronological age, was not related to epigenetic age acceleration, it 
was associated with mortality risk factors including overweight/
obesity, diabetes, heavy alcohol use and depression. Biological age 
acceleration may be an important mechanism linking affective mood 
disorders to age-related disease. Advances in life expectancies have 
led to an increased prevalence of age-related morbidities. Targeting 
the process of aging itself, through changes in living conditions, be-
haviours or therapeutic interventions, may help more people expe-
rience healthy aging.
4  | E XPERIMENTAL PROCEDURES
4.1 | Cohort and covariate information
The Airwave Health Monitoring Study is an occupational cohort of 
employees of 28 police forces from across Great Britain. Full details of 
the cohort, methods and data access are available (Elliott et al., 2014). 
The study started recruitment in 2006 and now contains 53,280 
participants. The study received ethical approval from the National 
Health Service Multi-Site Research Ethics Committee (MREC/13/
NW/0588). At the baseline health screening, participants underwent 
health examination, self-completed a computer questionnaire and 
provided urine and blood samples. Blood samples were spun at the 
health clinic, and the biological samples were stored in a Thermoporter 
(LaminarMedica) and sent overnight from the clinics for next-day anal-
ysis of standard clinical chemistry tests or were frozen at −80°C for 
long-term storage. DNA samples and plasma for metabolomic analysis 
were extracted from blood collected in EDTA tubes.
Important covariates in the analysis were categorized from 
self-report or clinical data as follows: ethnicity was defined as 
“white” or otherwise. Marital status was defined as living with 
partner or otherwise. Income was defined as low, medium or high, 
based on thirds of total net household income after adjustment 
for the number of dependant household members. Alcohol use 
was classed as nondrinker, moderate drinker (≤14 alcohol units/
week for women and ≤21 alcohol units/week for men) or heavy 
drinker (> 14 alcohol units/week for women and >21 alcohol units/
week for men). Hypertension was defined as ether reported di-
agnosis or systolic blood pressure ≥ 140 mmHg or diastolic blood 
pressure ≥ 90 mmHg. Diabetic status was defined as nondia-
betic (no diagnosis and HbA1c < 6.5%), or diabetic (diagnosis or 
HbA1c ≥ 6.5%). Physical activity was defined as low, moderate or 
high based on the scoring protocol of the International Physical 
Activity Questionnaire (The IPAQ Group, 2016). Weekly reported 
average consumption of fruit, vegetables, red meat, and fish from a 
food-frequency questionnaire was categorized into thirds, as low, 
medium and high consumption.
4.2 | Psychological instruments
The Patient Health Questionnaire—9 depression questionnaire was 
used to define participants as “normal (i.e., no depression),” “minimal 
symptoms of depression” or as a “depression case” (Kroenke, Spitzer, 
& Williams, 2001). The Hospital Anxiety and Depression Scale 
questionnaire was used to assess anxiety levels as “normal (i.e., no 
anxiety),” “borderline” and “anxiety case” (Zigmond & Snaith, 1983). 
Participants were asked if they had experienced a work-related 
traumatic incident in the previous six months. Those who reported 
a traumatic incident were then asked to complete a brief screen-
ing instrument for post-traumatic stress disorder (PTSD) (Brewin 
et al., 2002). Participants were thus classed into three categories: 
“not experienced traumatic incident in past 6 months,” “experienced 
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traumatic incident in past 6 months without leading to PTSD” and 
“experienced traumatic incident in past 6 months leading to PTSD”.
4.3 | Metabolomic data acquisition
Metabolomic analysis of serum and urine was performed at the 
National Phenome Centre, based at Imperial College London. 
Samples were randomly sorted and thawed to 4°C, centrifuged to 
remove particulate matter, and the supernatant dispensed across 
dedicated 96-well plates for each assay. Study reference (SR) sam-
ples, a pool of all samples for each matrix in the study, and long-term 
reference (LTR) samples, a pool of samples external to study, were 
included in each analytical run to allow for quantification and correc-
tion of technical variation. Samples were maintained at 4°C during 
preparation for, and while awaiting, acquisition. Metabolomic data 
was acquired from urine using nuclear magnetic resonance spec-
troscopy (NMR, NOESY experiment) and ultra-performance liquid 
chromatography–mass spectrometry (UPLC-MS, hydrophilic inter-
action chromatography and reversed-phase chromatography in both 
positive and negative modes) and from serum using NMR (CPMG 
experiment and lipoprotein subclass analysis) and UPLC-MS (hydro-
philic interaction chromatography and lipid-targeted reversed-phase 
chromatography in both positive and negative modes) (Table 1). Full 
details of metabolomic data acquisition and preprocessing, including 
processes to de-noise the data for technical variation such as batch 
and run-order, are given in the Supporting Information.
4.4 | Metabolomic age modelling
Untargeted NMR data sets were glog-transformed (Parsons, Ludwig, 
Gunther, & Viant, 2007), the quantified BiLISA data were log-trans-
formed, and the UPLC-MS data were log-transformed, following unit 
addition to every value to allow transformation of zero values. Data 
were then mean centred and scaled to unit variance.
Predictive models of age were constructed using elastic net re-
gression (Zou & Hastie, 2005) in the “glmnet” package (Friedman, 
Hastie, & Tibshirani, 2010) in R ver. 3.3.2. using a multi-step process. 
Elastic net model parameters, α (that defines mixing between lasso 
and ridge penalties) and λ (overall strength of penalty), were found 
following 10-fold cross-validation. A line search across α, between 0 
and 1 in 0.01 increments, was performed to find the minimum mean 
cross-validated error (MSE) using the optimal value of λ found using 
the “cvfit” command for each α value. The following steps were boot-
strapped 100 times, re-sampling the selected metabolomic data sets 
into different independent training (80%) and tests set (20%). Step 1 
Stability analysis: Elastic net regression models were fitted on 100 fur-
ther subsamples of the training data set (a random subsample of 80% 
each time). The metabolic features selected in each model were stored 
for each iteration. Step 2 Metabolomic data restriction: On the same 
subsample for 101 iterations, the number of metabolic features avail-
able to build an elastic net model was restricted by the percentage of 
iterations in step 1 that a feature was selected, moving from 100% to 
0%, in 1% decrements for each subsequent iteration. The correlation 
between predicted and chronological age in remaining subsampled 
20% of training set was stored for each iteration and the percentage 
restriction value that gave the best correlation was chosen for the 
final metabolic feature restriction in step 3. Step 3 Final model build-
ing: On the complete training data set, a final elastic net model was 
constructed using metabolic features restricted to those present in 
a set percentage of models, as found in step 2. Step 4 Validation: We 
assessed performance of models through Pearson's correlation (r) and 
mean absolute error (MAE) in the testing sets for each bootstrap.
To assess performance of each metabolomic platform, we first 
modelled age using each platform separately.
To define a metabolomic age combining platforms, we tested 
model performance using different platform combinations to im-
prove practicality by using fewer metabolomic platforms since there 
is potential redundancy between metabolomic data sets (the same 
metabolite measured in multiple platforms) and because the differ-
ent data structures of the various platforms may influence the vari-
able selection process. We performed a leave-platform-out analysis 
by repeating the modelling process on a combined data set with one 
metabolomic platform left out each time. Platforms were removed 
from further analysis if model performed better (lower MSE calcu-
lated from 10-fold cross-validation) with their exclusion. We con-
tinued this process leaving further platforms out each time until no 
improvement in MSE was observed.
Metabolomic age was assigned to each participant based on the 
average predicted age from across all 100 bootstrapped models based 
on the final included platforms. Metabolomic age acceleration (mAA) 
was then defined as the difference between chronological age and me-
tabolomic age, adjusted on chronological age as previously defined for 
DNA methylation age acceleration (Horvath, 2013). That is, we define 
mAA as the residuals of a linear regression between the chronological 
age and metabolomic age difference, with chronological age itself.
In sensitivity analyses, we repeat the modelling processes (on the 
final included platforms) using participants from different study cen-
tres, representing different regional police services, as the testing 
sets instead of bootstrapped sampling.
We also repeated the bootstrapping processing forcing BMI into 
each model. mAA was then defined in this analysis as the difference 
between chronological age and metabolomic age, adjusted on both 
chronological age and BMI.
4.5 | Metabolic feature and pathway annotation
Tentative annotations were provided for mass spectrometry-based 
metabolic features based on m/z searches across the Human me-
tabolome database (Wishart et al., 2018), for the ion forms M+2H, 
M+H+NH4, M+NH4, M+H, M+ACN+H, M+CH3OH+H, M+Na, M+K, 
2M+H at ±8 ppm mass tolerance.
For five UPLC-MS-based metabolic features that were both tenta-
tively annotated by exact mass within our metabolomic age model and 
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also available in repeat measurements within the Northern Finnish Birth 
Cohort data set, we performed further annotation procedures. Two of 
these annotations, for citrate (as in-source fragmentation product) and 
leucine (M+Na ionic form), were supported by matching retention times 
and accurate mass to an internal reference standard database.
Significantly enriched metabolic pathways were predicted using 
the Mummichog program ver. 1.1.0 (Li et al., 2013), through the 
MetaboAnalyst platform (Chong et al., 2018). The enrichment analy-
sis compared the sLPOS-, uHPOS- and uRPOS-derived features that 
were present in ≥75% of models (the feature list), to features present 
in these data sets but not selected into ≥75% of models (the reference 
list). The algorithm searches tentative compound lists from metabolite 
reference databases against an integrated model of human metabo-
lism to identify functional activity. Fisher's exact tests are used to infer 
p-values, which are adjusted for type I error through a pathway permu-
tation procedure and for likelihood of pathway enrichment among sig-
nificant features as compared to pathways identified among the entire 
compound set present in reference list (the entire metabolome data 
set), considering the probability of mapping the significant m/z fea-
tures to pathways. Mummichog parameters were set to match against 
ions included in the “positive mode” setting at ±5 ppm mass tolerance. 
Visualization of enriched pathways on the KEGGscape network was 
performed through the MetaboAnalyst platform (Chong et al., 2018).
4.6 | Metabolite validation in the Northern Finnish 
Birth Cohort 1966
The Northern Finnish Birth Cohort 1966 is a prospective birth co-
hort that sampled 12,058 live births in 1966, including 96.3% of all 
births in the regions of Oulu and Lapland in Finland (Rantakallio, 
1988). Fasting blood samples were collected at follow-up of par-
ticipants at ages 31 and 46 years and stored at −80°C for subse-
quent biomarker profiling. A high-throughput NMR metabolomics 
platform was used for the analysis of 149 metabolic measures 
(Soininen, Kangas, Wurtz, Suna, & Ala-Korpela, 2015). This metab-
olomics platform provides simultaneous quantification of routine 
lipids and lipid concentrations of 14 lipoprotein subclasses and 
major sub-fractions, and further quantifies abundant fatty acids, 
amino acids, ketone bodies and gluconeogenesis-related metabo-
lites in absolute concentration units.
We assessed changes of 11 metabolites, that were available in 
this data set and also included in our predictive model, between 
these two sampling points using 1-tailed t tests. We used a validation 
p-value of .005 (.05/11 tests) to infer statistical significance.
4.7 | DNA methylation analysis
Full details of DNA methylation data acquisition and preprocessing 
are given in the Supporting Information.
DNA methylation age was computed according to the algorithm 
described by Hannum et al. (2013) based on 71 blood-specific CpG 
sites and the algorithm of Horvath (2013) based on 353 nontis-
sue-specific CpG sites. DNA methylation phenotypic age was com-
puted according to the algorithm of Levine et al, based on 513 CpG 
sites (Levine et al., 2018). Age acceleration (AA) was defined as the 
difference between epigenetic and chronological age. Since AA 
could be correlated with chronological age and WBC percentage, 
we computed the so-called intrinsic epigenetic age acceleration for 
Horvath and Hannum age (Chen et al., 2016), which is defined as 
the residuals from the linear regression of AA with chronological 
age and blood cell counts (measured using flow cytometry) for neu-
trophils, lymphocytes, monocytes and eosinophils. Phenotypic age 
acceleration was defined as residuals from the linear regression of 
AA with chronological age (Levine et al., 2018).
4.8 | Analysis of risk factors of biological age 
acceleration
We analysed associations between mortality risk factors and age 
acceleration scores in separate adjusted linear regression models, 
using age acceleration scores as the dependent variables and the risk 
factor as the independent variable. To allow comparison across risk 
factors and age scores, the adjustment set, included in all models, 
was chosen a priori. It included demographic variables (sex, ethnic-
ity, study centre, income), the 25 × 25 main NCD risk factors, (hy-
pertension, diabetes, BMI, smoking, alcohol intake, physical activity) 
and dietary indicators (red meat, fish, fruit and vegetable consump-
tion). We corrected for assessment of multiple exposures using the 
5% false discovery rate (Benjamini & Hochberg, 1995).
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